SCHEMBL2060733

SCHEMBL2060733

Cc1nc2cc([N+](=O)[O-])ccc2o1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.61
MEN1 O00255 3/20 0.61
KMT2A Q03164 3/20 0.61
RAB9A P51151 9/20 0.60
NPC1 O15118 7/20 0.60
MAPT P10636 6/20 0.60
SMN1; SMN2 Q16637 3/20 0.60
MMP2 P08253 2/20 0.57
MMP9 P14780 2/20 0.57
MMP8 P22894 2/20 0.57
MMP13 P45452 2/20 0.57
MCL1 Q07820 1/20 0.57
ATM Q13315 1/20 0.57
POLB P06746 1/20 0.51
GAA P10253 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
HTT P42858 2/20 0.46
KDM4E B2RXH2 1/20 0.46
TP53 P04637 1/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2062399 0.87 MAPT (0.60) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL13054081 0.83 RAB9A (0.56) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL1191852 0.82 RAB9A (0.50) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL2420144 0.81 RAB9A (0.61) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL15172875 0.81 RAB9A (0.61) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL11443651 0.81 MEN1 (0.62) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL29362134 0.81 RAB9A (0.61) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL10173106 0.80 RAB9A (0.65) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL2244450 0.80 RAB9A (0.60) ALDH1A1MEN1KMT2ARAB9ANPC1
SCHEMBL10173135 0.80 RAB9A (0.60) ALDH1A1MEN1KMT2ARAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12227524-B2 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2025-02-18 US disclosed
US-20220153756-A1 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2022-05-19 US disclosed
US-20220153756-A1 ANTI-INFECTIVE COMPOUNDS INSTITUT PASTEUR KOREA (KR) 2022-05-19 US disclosed
US-11279714-B2 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2022-03-22 US disclosed
CN-107027307-B Anti-infective compounds 韩国巴斯德研究所 2020-12-22 CN disclosed
EP-3157904-B1 ANTI-INFECTIVE COMPOUNDS PASTEUR INSTITUT KOREA (KR) 2020-11-18 EP disclosed
EP-3157904-B1 ANTI-INFECTIVE COMPOUNDS PASTEUR INSTITUT KOREA (KR) 2020-11-18 EP disclosed
EP-2589592-B1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM CORP (JP) 2018-08-22 EP disclosed
EP-2684874-B1 Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors CEPHALON INC (US) 2017-05-17 EP disclosed
US-20170121349-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2017-05-04 US disclosed
US-20070255057-A1 Mono-nitration of aromatic compounds via nitrate salts CEDILOTE MIALL 2007-11-01 US disclosed
US-20070255057-A1 Mono-nitration of aromatic compounds via nitrate salts CEDILOTE MIALL 2007-11-01 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed
US-20060223868-A1 Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) ASTRAZENECA AB (SE) 2006-10-05 US disclosed
EP-1622884-A1 NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). AstraZeneca AB (SE) 2006-02-08 EP disclosed
WO-2004096784-A1 NEW HETEROCYCLIC AMIDES EXHIBITING AN INHIBITORY ACTIVITY AT THE VANILLOID RECEPTOR 1 (VR1). ASTRAZENECA AB (SE) 2004-11-11 WO disclosed
EP-0561475-B1 Bleachable polymeric filter dyes EASTMAN KODAK CO (US) 2000-03-01 EP disclosed
EP-0561475-A1 Bleachable polymeric filter dyes EASTMAN KODAK COMPANY (US) 1993-09-22 EP disclosed
US-5244994-A Benzoxazole styryl chromophore attached to polymer, X-ray films, high speed EASTMAN KODAK COMPANY (US) 1993-09-14 US disclosed
EP-0029720-A1 The development of lithographic films MINNESOTA MINING AND MANUFACTURING COMPANY (US) 1981-06-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060223868-A1 Heterocyclic amides exhibiting and inhibitory activity at the vanilloid receptor 1(vr1) AVPR1A, AVPR2, TRPV1 ALDH1A1 726/4885MEN1 2859/4885KMT2A 3280/4885
US-20220153756-A1 ANTI-INFECTIVE COMPOUNDS RABGGTB, ELANE, SERPINB1 ALDH1A1 3932/4885MEN1 3685/4885KMT2A 4781/4885
US-12227524-B2 Anti-infective compounds RABGGTB, ELANE, SERPINB1 ALDH1A1 3932/4885MEN1 3685/4885KMT2A 4781/4885
US-11279714-B2 Anti-infective compounds FNTB, LSS, PGLS ALDH1A1 1595/4885MEN1 3545/4885KMT2A 4578/4885
US-20070255057-A1 Mono-nitration of aromatic compounds via nitrate salts NOS2, NOS3, NOS1 ALDH1A1 722/4885MEN1 2021/4885KMT2A 2556/4885
US-20170121349-A1 Anti-Infective Compounds FNTB, LSS, PGLS ALDH1A1 1595/4885MEN1 3545/4885KMT2A 4578/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.